🇺🇸 FDA
Patent

US 11389497

Pharmaceutical composition for treating cancer

granted A61KA61K2236/00A61K31/191

Quick answer

US patent 11389497 (Pharmaceutical composition for treating cancer) held by Prime Bio, Inc. expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Prime Bio, Inc.
Grant date
Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K2236/00, A61K31/191, A61K31/375, A61K36/53